994 related articles for article (PubMed ID: 11929823)
41. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
42. Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.
Nagarkatti M; Clary SR; Nagarkatti PS
J Immunol; 1990 Jun; 144(12):4898-905. PubMed ID: 1972170
[TBL] [Abstract][Full Text] [Related]
43. Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer.
Chen A; Liu S; Park D; Kang Y; Zheng G
Cancer Res; 2007 Feb; 67(3):1291-8. PubMed ID: 17283166
[TBL] [Abstract][Full Text] [Related]
44. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
Xu JJ; Yao K; Yu CJ; Chen X; Lu MP; Sun H; Li BZ; Ding CN; Zhou F
Auris Nasus Larynx; 2006 Dec; 33(4):441-6. PubMed ID: 16934422
[TBL] [Abstract][Full Text] [Related]
45. Self-thyroid epithelial cell (TEC)-reactive CD8+ T cell lines/clones derived from autoimmune thyroiditis lesions. They recognize self-thyroid antigens directly on TEC to exhibit T helper cell 1-type lymphokine production and cytotoxicity against TEC.
Sugihara S; Fujiwara H; Niimi H; Shearer GM
J Immunol; 1995 Aug; 155(3):1619-28. PubMed ID: 7543527
[TBL] [Abstract][Full Text] [Related]
46. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
47. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
48. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
49. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
50. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
[TBL] [Abstract][Full Text] [Related]
51. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
52. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
53. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
54. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
55. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
56. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
Zhang W; He L; Cao X
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
[TBL] [Abstract][Full Text] [Related]
57. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.
Wang L; Qi X; Sun Y; Liang L; Ju D
Cancer Gene Ther; 2002 Oct; 9(10):819-24. PubMed ID: 12224022
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
59. NK 1+ CD4- CD8- alphabeta T cells in the peritoneal cavity: specific T cell receptor-mediated cytotoxicity and selective IFN-gamma production against B cell leukemia and myeloma cells.
Sugie T; Kubota H; Sato M; Nakamura E; Imamura M; Minato N
J Immunol; 1996 Nov; 157(9):3925-35. PubMed ID: 8892624
[TBL] [Abstract][Full Text] [Related]
60. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]